Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,799.50
Bid: 1,796.00
Ask: 1,796.50
Change: 19.00 (1.07%)
Spread: 0.50 (0.028%)
Open: 1,784.00
High: 1,799.50
Low: 1,780.00
Prev. Close: 1,780.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK publishes Annual Report 2023

1 Mar 2024 12:15

RNS Number : 2981F
GSK PLC
01 March 2024
 

 

GSK plc

(the 'Company')

 

Publication of Annual Report 2023

 

 

The Company has today published on its website www.annualreport.gsk.com its Annual Report for the year ended 31 December 2023 ('Annual Report 2023').

 

In compliance with Listing Rule 9.6.1R of the UK Financial Conduct Authority ('FCA'), the Annual Report 2023 has been submitted to the FCA's National Storage Mechanism ('NSM') and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

A hard copy version of the Annual Report 2023 and the Notice of Annual General Meeting 2024 ('AGM Notice') will be sent to those shareholders who have elected to receive paper communications on or around 25 March 2024. The AGM Notice will be made available to shareholders who have not elected to receive paper communications on the same date.

 

This announcement is not a substitute for reading the Annual Report 2023 in full.

 

Additional Information

 

For the purposes of complying with the FCA's Disclosure and Transparency Rules ('DTRs') and the requirements imposed on issuers through the DTRs, information required to be communicated with the media in unedited full text was included in the Annual Report 2023. The Annual Report 2023 was submitted to the NSM and will shortly be available for inspection. It is also available on the Company's website as noted above.

 

This announcement is made in accordance with DTR 6.3.5R(1A).

 

V A Whyte

Company Secretary

 

1 March 2024

 

?

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSEAADFEFALEFA
Date   Source Headline
9th Dec 20214:35 pmRNSDirector/PDMR Shareholding
7th Dec 202112:00 pmRNSMedicago/GSK COVID-19 vaccine positive Ph3 data
7th Dec 20217:07 amRNSSotrovimab retains its activity vs Omicron variant
2nd Dec 20217:02 amRNSSotrovimab retains its activity vs Omicron variant
1st Dec 202111:05 amPRNTotal Voting Rights
24th Nov 20214:17 pmRNSDirector/PDMR Shareholding
24th Nov 20214:00 pmRNSGSK publishes provisional 2022 dividend dates
23rd Nov 20213:06 pmRNSDirector/PDMR Shareholding
17th Nov 20217:00 amRNSNucala approved in Europe for more indications
15th Nov 20214:37 pmRNSBlock listing Interim Review
12th Nov 202112:00 pmRNSPhase III IM administration data for sotrovimab
12th Nov 20219:23 amRNSDirector/PDMR Shareholding
10th Nov 202111:28 amRNSDirector/PDMR Shareholding
5th Nov 20215:33 pmRNSGSK shares positive Phase III data for daprodustat
1st Nov 20215:11 pmRNSTotal Voting Rights
27th Oct 20212:23 pmRNSDirector/PDMR Shareholding
27th Oct 202112:00 pmRNS3rd Quarter Results
27th Oct 20219:00 amRNSDirectorate Change
15th Oct 20212:41 pmRNSDirector/PDMR Shareholding
14th Oct 20214:31 pmRNSDirector/PDMR Shareholding
14th Oct 20214:28 pmRNSDirector/PDMR Shareholding
13th Oct 20211:55 pmRNSDirector/PDMR Shareholding
12th Oct 20213:17 pmRNSDirector/PDMR Shareholding
12th Oct 20211:36 pmRNSDirector/PDMR Shareholding
12th Oct 20211:33 pmRNSDirector/PDMR Shareholding
12th Oct 20211:30 pmRNSDirector/PDMR Shareholding
12th Oct 20211:28 pmRNSDirector/PDMR Shareholding
1st Oct 202111:54 amRNSTotal Voting Rights
24th Sep 20215:28 pmRNSDirector/PDMR Shareholding
22nd Sep 20213:58 pmRNSDirector/PDMR Shareholding
20th Sep 20212:42 pmRNSDirector Declaration
13th Sep 20215:26 pmRNSDirector/PDMR Shareholding
9th Sep 20214:42 pmRNSDirector/PDMR Shareholding
7th Sep 20214:54 pmRNSDirector/PDMR Shareholding
3rd Sep 20219:32 amRNSDirector/PDMR Shareholding
1st Sep 202111:44 amRNSTotal Voting Rights
31st Aug 20217:00 amRNSSK bio & GSK start Ph3 Covid-19 vaccine trial
25th Aug 20212:01 pmRNSDirector/PDMR Shareholding
23rd Aug 20214:39 pmRNSDirector/PDMR Shareholding
13th Aug 20219:38 amRNSDirector/PDMR Shareholding - amendment
11th Aug 20212:18 pmRNSDirector/PDMR Shareholding
11th Aug 202112:34 pmRNSDirector/PDMR Shareholding
5th Aug 20219:00 amRNSBlock Listing Application
2nd Aug 20212:23 pmRNSTotal Voting Rights
28th Jul 20215:32 pmRNSDirector/PDMR Shareholding
28th Jul 202112:00 pmRNS2nd Quarter Results
26th Jul 20214:59 pmRNSDirector/PDMR Shareholding
23rd Jul 20212:32 pmRNSBoard Committee Changes
22nd Jul 20212:45 pmRNSCEO Designate of new Consumer Healthcare company
16th Jul 202112:00 pmRNSGSK announces daprodustat phase 3 headline results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.